Bavachinin has previously been shown to modulate diverse signaling pathways in other cancer models, including p53/BCL-2/BAX signaling in DMH-induced colon cancer (16), inhibition of the cholesterol-synthesis enzyme FDFT1 via the AKT/mTOR/SREBP-2 pathway (17), and G2/M cell-cycle arrest through p38/p21Waf1/Cip1 activation in non-small-cell lung cancer (SCLC) (13). This evidence concerns the gene BCL2 and non-small cell lung carcinoma.